SDP Completes Tolero Buy To Build Oncology Ahead Of Key Expiry

Sumitomo Dainippon Pharma has completed the acquisition of US specialty company Tolero for up to $780m in a move that boosts the mid-sized Japanese firm's presence in oncology ahead of a looming major patent expiry for its top-selling product.